EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Safety and Effectiveness of High‐Intensity Statins Versus Low/Moderate‐Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL‐C Goals: A Systematic Review and Meta‐Analysis

Hamidreza Soleimani iD, Asma Mousavi iD, Shayan Shojaei, Kiarash Tavakoli, Dorsa Salabat, Farid Farahani Rad, Mani K Askari iD, John Nelson, Mohammed Ruzieh, Kaveh Hosseini iD

Clinical Cardiology · 2024

DOI: 10.1002/clc.24334 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Hamidreza Soleimani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Ezetimibe, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol, LDL, Drug Therapy, Combination. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It remains controversial whether adding ezetimibe to low/moderate‐intensity statins has a more beneficial impact on the treatment efficacy and safety of patients with existing atherosclerotic cardiovascular disease (ASCVD) compared to high‐intensity statin regimens. Hypothesis A combination of low/moderate‐intensity statins plus ezetimibe might be more effective and safer than high‐intensity statin monotherapy.

Methods

We searched databases for randomized controlled trials comparing lipid profile alterations, drug‐related adverse events, and MACE components between high‐intensity statin monotherapy and low/moderate‐intensity statin plus ezetimibe combination therapy. Pooled risk ratios (RR), mean differences (MD), and 95% confidence intervals (95% CI) were estimated using a random‐effects model.

Results

Our comprehensive search resulted in 32 studies comprising 6162 patients treated with monotherapy against 5880 patients on combination therapy. Combination therapy was more effective in reducing low‐density lipoprotein cholesterol (LDL‐C) levels compared to monotherapy (MD = −6.6, 95% CI: −10.6 to −2.5); however, no significant differences were observed in other lipid parameters. Furthermore, the combination therapy group experienced a lower risk of myalgia (RR = 0.27, 95% CI: 0.13–0.57) and discontinuation due to adverse events (RR = 0.61, 95% CI: 0.51–0.74). The occurrence of MACE was similar between the two treatment groups.

Conclusions

Adding ezetimibe to low/moderate‐intensity statins resulted in a greater reduction in LDL‐C levels, a lower rate of myalgia, and less drug discontinuation compared to high‐intensity statin monotherapy in patients with existing cardiovascular disease. However, according to our meta‐analysis, the observed reduction in LDL‐C levels in the combination group did not correlate with a reduction in MACE compared to the high‐intensity statin group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLDrug Therapy, CombinationAnticholesteremic AgentsHumansTreatment OutcomeAtherosclerosisBiomarkers

Stichwörter der Autor:innen

atherosclerosisezetimibemeta‐analysisstatinsystematic review

Substanzen

EzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLAnticholesteremic AgentsBiomarkers

Autor:innen und Institutionen

  • Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Medicine, University of Toledo, Toledo, Ohio, USA.
  • California Cardiovascular Institute, University of Louisville School of Medicine, Fresno, California, USA.
  • Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainsville, Florida, USA.

ORCID-Profile: Hamidreza Soleimani, Asma Mousavi, Mani K Askari, Kaveh Hosseini

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Soleimani, H., Mousavi, A., Shojaei, S., Tavakoli, K., Salabat, D., Farahani Rad, F., Askari, M. K., Nelson, J., Ruzieh, M., & Hosseini, K. (2024). Safety and Effectiveness of High‐Intensity Statins Versus Low/Moderate‐Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL‐C Goals: A Systematic Review and Meta‐Analysis. Clinical Cardiology. https://doi.org/10.1002/clc.24334

Vancouver

Soleimani H, Mousavi A, Shojaei S, Tavakoli K, Salabat D, Farahani Rad F, et al. Safety and Effectiveness of High‐Intensity Statins Versus Low/Moderate‐Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL‐C Goals: A Systematic Review and Meta‐Analysis. Clinical Cardiology. 2024. doi:10.1002/clc.24334

BibTeX
@article{Soleimani2024,
  author = {Soleimani, Hamidreza and Mousavi, Asma and Shojaei, Shayan and Tavakoli, Kiarash and Salabat, Dorsa and Farahani Rad, Farid and Askari, Mani K and Nelson, John and Ruzieh, Mohammed and Hosseini, Kaveh},
  title = {Safety and Effectiveness of High‐Intensity Statins Versus Low/Moderate‐Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL‐C Goals: A Systematic Review and Meta‐Analysis},
  journal = {Clinical Cardiology},
  year = {2024},
  doi = {10.1002/clc.24334}
}
Kostenlos starten →